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Madeleine, Orléans, FranceAbstractPrimary Epstein-Barr virus infection (PEI) is acquired increasingly later in life in developed countries, involving a growing number of adults. No
studies have examined the effect of age on PEI. We conducted a prospective, single-centre, noninterventional survey to assess the clinical and
economic effects of PEI care according to age. We included all serology-conﬁrmed cases observed in all departments of a large regional
hospital. Clinical and biologic data, therapeutics and costs of care were examined. Over a 6-year period, we included 292 subjects (148
children and 144 adults) with a median age of 15.4 years (range 9 months to 79 years). Adults were hospitalized more often (83% vs.
60%) and for longer periods of time (median 4 days vs. 2 days) than children (p  0.0001 for both). Two adults required a secondary
transfer into the intensive care unit, although no children did. Typically, adults showed higher levels of activated lymphocytes and liver
abnormalities. They also required the use of systemic corticosteroids more often (45% vs. 23%, p < 0.0001) and for longer periods of
time (median 7 days vs. 3 days, p 0.02) than children. Overall, the costs were signiﬁcantly higher for adults than for children (median,
V1940 vs. V1130, p < 0.0001), mainly because of the frequency and duration of hospitalizations. Age increases the immune response and
clinical severity of PEI, resulting in substantial additional costs for the community. Better recognition of the disease in adults could
shorten the average length of hospital stay.
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decades in the age of acquisition of Epstein-Barr virus (EBV)
from early childhood to adolescence or even adulthood [1–4].
Several seroepidemiologic studies have consistently linked thisClinical Microbiology and Infection © 2015 European Society of Cshift to the overall improvement of the economic level and
sanitary conditions of the populations concerned [4–7].
Meanwhile, an increase in the frequency of hospitalizations for
primary EBV infection (PEI) has been reported [1,8].
PEI in young children is often asymptomatic or manifests as a
mild and nonspeciﬁc illness, whereas most adolescents and
adults present with a typical infectious mononucleosis syn-
drome [3,9]. In a large prospective study conducted in the early
1990s, up to 85% of young adults with suspected infectious
mononucleosis were hospitalized [10]. Moreover, a growing
incidence of severe (and sometimes life-threatening) forms of
infectious mononucleosis in apparently immunocompetent
adults has been reported by some authors [8,10–12].Clin Microbiol Infect 2015; 21: 1041.e1–1041.e7
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.07.015
1041.e2 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMIHere we report on a prospective observational survey that
we conducted to assess how age affects the severity of PEI and
its costs in a French hospital.Patients and MethodsStudy design and setting
This study was a prospective, noninterventional survey in a
large (1250 beds) tertiary-care centre in France. From 2008 to
2013, we systematically identiﬁed in- and outpatients who
presented at our hospital with a suspicion of PEI by means of a
triple-alert system, which includes physicians, laboratories and
an electronic database. Physicians from all departments and
biologists were asked to report any suspected case of PEI to the
investigators (i.e. patients presenting with a classic triad or any
other feature compatible with a viral infection together with
activated lymphocytes on the blood count). Last, an electronic
database system identiﬁed patients coded with PEI as a main or
associated diagnosis (B27.0) according to hospital discharge
codes.
The patients provided their consent to participate after being
orally informed of the study protocol. This study was approved
by the Orléans Hospital ethics committee.
Participants
Data from all suspected cases were collected soon after the
patient’s discharge (so as not to inﬂuence the physician’s clinical
ﬁndings, diagnosis, decisions of care or therapeutics) and
reviewed by the scientiﬁc committee. Cases were deﬁnitely
validated (and kept for analyses) if they met the following
deﬁnition: clinical feature suggestive of PEI (as asserted by a
physician’s diagnosis) together with biologic evidence of acute
EBV infection, i.e. positive IgM anti-VCA (with or without IgG)
and negative IgG anti-EBNA antibodies (enzyme immunosor-
bent assay; Liaison, DiaSorin, Saluggia, Italy) or a positive EBV
PCR result in whole blood in the absence of anti-VCA and anti-
EBNA antibodies (real-time PCR; EBV R-gene, bioMérieux,
Marcy l’Étoile, France).
Outcomes
The primary end point was to compare the clinical severity of
PEI in a paediatric setting (i.e. patients aged <15 years and 3
months, henceforth called children) vs. those in an adult setting
(i.e. patients aged 15 years and 3 months, henceforth called
adults) by means of their respective admission rates, duration of
stay in the hospital, intensive care unit (ICU) transfers and
death rates. Secondary end points were used to describe how
age affected the clinical and laboratory ﬁndings, therapeutic
options and costs of care. Last, we aimed to identify factorsClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectpredicting increased severity during PEI, which was assessed by
the hospitalization rate and duration of stay.
Covariates
All (written or electronic) clinical, biologic, radiologic and ther-
apeutic data were reviewed, summarized and anonymously
computerized in a standardized form for analysis. The baseline
data (i.e. at the time of hospital admission) included the following:
demographic data, medical history, and clinical and laboratory
ﬁndings. The follow-up data included the following: all reported
clinical events until hospital discharge, therapeutic drugs used and
any invasive therapeutic or diagnostic procedures.
The costs of hospital stay were estimated using the French
Diagnosis Related Groups method. The diagnoses and pro-
cedures were encoded by the physicians at hospital discharge
and were adjusted on the basis of the length of stay. All PEI cases
were recalculated using the 2008 algorithm; then costs were
standardized at the claim level to 2014, using an actualization
rate of 4% per year, as recommended by French guidelines.
Statistical analysis
The data were expressed as median (interquartile range (IQR)),
mean ± standard deviation or percentage values. Between-group
differences were compared by the chi-square or Fisher’s exact
tests for categorical variables and the unpaired t test, Mann-
Whitney U test or Kruskal-Wallis test for continuous variables.
Associations between outcomes of interest and various factors
were tested by a multivariate logistic regression analysis. All p
values were two tailed, and signiﬁcance was set at the 0.05 level.ResultsParticipants
Over a 6-year period (2008–2013), 292 cases of PEI were
included comprising 148 children (51%) and 144 adults (49%)
(Fig. 1). Overall, there were 155 male (53%) and 137 female
(47%) subjects. The annual incidence was stable over time. The
median age of the patients presenting with PEI was 15.4 years
(IQR 5.1–21.4), ranging from 9 months to 79 years, and was
stable over time. The main ethnic population was white
(87.2%), followed by North African (7.1%), sub-Saharan African
(5.3%) and Asian (0.4%) populations. Overall, 208/292 (71%) of
all people presenting with PEI at our establishment were hos-
pitalized for a median of 3 days (IQR 2–5). The hospitalization
rate was stable over time.
Main outcomes
Overall, adults presenting with PEI were more likely to be hos-
pitalized than children: 83% vs. 60% (p < 0.0001). Moreover,ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1041.e1–1041.e7
FIG. 1. Flow chart of patients with primary Epstein-Barr virus infection included in the survey.
CMI Hocqueloux et al. Burden of hospitalizations for EBV 1041.e3adults who were hospitalized had a longer duration of stay (me-
dian 4 days, IQR 2–5) than children (median 2 days, IQR 1–4; p
0.0001). Two adults required a secondary transfer into an ICU (a
75-year-old woman with life-threatening hemophagocytic lym-
phohistiocytosis (HL) and a 28-year-old woman with acute
myocarditis, neither of whom had previous debilitating condi-
tions), whereas ICU transfer did not occur among children (p 0.2).
One of these adults died from multiple organ failure complicating
untreatable HL; there were no deaths among children (p 0.5).
Secondary outcomes
The main clinical and laboratory characteristics of the patients
at hospital venue are summarized according to age group inClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfeTable 1. Notably, two patients had only immunosuppressive
conditions before PEI (HIV infection in a child and ankylosing
spondyloarthritis treated by adalimumab in a woman).
Clinical ﬁndings
Overall, the patients presented to our hospital a median of 6
days (IQR 4–9) after the onset of symptoms. The most
frequent complaints and signs are summarized in Table 1.
Although the classic triad (fever, sore throat and lymphade-
nopathy) was equally balanced between children and adults (63
vs. 68%, p 0.8), children were more likely to have nonspeciﬁc
ﬁndings (i.e. rash, cough, diarrhea, runny nose, dehydration and
convulsions) and to be nonwhite (Table 1). Conversely, adultsctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1041.e1–1041.e7




pan Value n Value
Demographic data 148 144
Age (years) 5.2 (2.4–9.8) 21.5 (18.5–25.1) <0.0001




Clinical ﬁndingsc 148 144
Time from ﬁrst symptoms
to hospital venue (days)
4 (3–8) 7 (5–13) <0.0001
Symptoms
Sore throat 77.7 81.3 0.47
Odynophagia 37.2 49.3 0.04
Intense fatigue 35.1 40.3 0.39
Flulike syndrome 6.1 45.8 <0.0001
Headache 13.5 32.6 <0.0001
Abdominal pain 20.3 20.1 1.0
Anorexia 9.5 12.5 0.46
Respiratory discomfort 9.5 4.2 0.10
Signs
Fever (temperature >38°C) 93.9 88.2 0.10
Cervical lymphadenopathy 75.0 85.4 0.03




Vomiting 24.3 25.0 1.0
Rash 28.4 17.4 0.03
Splenomegaly 10.1 31.9 <0.0001
Cough 28.4 12.5 0.001
Runny nose 31.8 1.4 <0.0001
Hepatomegaly 4.1 21.5 <0.0001
Diarrhoea 19.6 4.9 0.0001
Eyelid edema 14.9 6.3 0.02
Weight loss 9.5 7.6 0.68
Jaundice 0.0 9.0 <0.0001
Laboratory ﬁndings in blood
Blood cell count 148 144
Neutrophils (cells/μL) 3620 2695 0.03
Total lymphocytes (cells/μL) 5910 5700 0.42
Percentage of atypical
lymphocytes
2 (0–11) 14 (4–23) <0.0001
Haemoglobin (g/dL) 12.5 13.9 <0.0001
Platelets (cells/μL) 197000 196500 0.09
Liver tests 85 133
Aspartate aminotransferase
(ULN)
1.3 (0.9–3.6) 3.6 (1.3–6.6) 0.0001
Alanine aminotransferase
(ULN)
1.4 (0.6–3.2) 5.0 (1.9–8.6) <0.0001
γ-Glutamyltransferase (ULN) 1.2 (0.3–3.2) 3.0 (1.3–6.1) 0.0001
Total bilirubin (ULN) 0.4 (0.3–0.7) 0.8 (0.4–1.3) <0.0001
Other markers
C-reactive protein (mg/L) 134 138 18 (7–33) 0.03
Procalcitonin (U/L) 59 10 0.32 (0.09–0.75) 0.65
EBV DNA virus load
(log/mL)
6 50 4.6 (2.7–4.5) 0.18
Data are presented as median (interquartile range) or %.
EBV, Epstein-Barr virus; ULN, upper limit of normal.
aMann-Whitney U test used for nonparametric continuous data, chi-square test for
dichotomous data.
bNorth or sub-Saharan African or Asian.
cReported are clinical ﬁndings documented in at least 5% of patients of one group.
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organs (i.e. lymph nodes, spleen and liver), severe odynophagia
and jaundice. Adults also more frequently had severe headache
that led to the application of a lumbar puncture: 11/144 (8%) vs.
2/148 (1%) for children (p 0.01) (Table 2).
Although the groups shared similar patterns of reasons that
led to hospitalization (fever, sore throat/odynophagia, rash,
hepatitis, abdominal pain, headache, lymphadenopathy and
vomiting were the most frequent), adults were more likely to
be hospitalized because of headache and hepatitis (13% and 15%Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectvs. 1% and 1% for children, p 0.001 and 0.0004, respectively),
whereas children were more likely to be hospitalized because
of fever (58% vs. 34%, p 0.0007) (Supplementary Table S1).
Laboratory ﬁndings
Compared to children, adults displayed substantially greater
amounts of activated lymphocytes in blood and elevated liver
test results (Table 1). Strong elevation in liver tests (i.e. greater
than 10 times the upper limit of normal) was observed in 18%,
15% and 12% of adults for alanine aminotransferase, aspartate
aminotransferase and γ-glutamyl transferase, respectively,
compared to 6%, 1% and 2% of children (p < 0.05 for all
comparisons). Nevertheless, no patients developed hepatic
failure. There were also no incidences of severe and symp-
tomatic neutropenia, anemia, thrombopenia or coagulation
disorder, except for the adult who died in the ICU from mul-
tiple organ failure with diffuse hemorrhages.
Treatments
Overall, the patients received symptomatic care, and none of
the patients were treated with antiviral drugs, according to
national practices. The patients complaining of severe odyno-
phagia were hydrated and fed intravenously until swallowing
had improved. Additionally, these patients were given systemic
corticosteroids (SCS). The second reason patients received
SCS was intense fatigue. Typically, SCS were ﬁrst administered
intravenously for 1 to 3 days (for hospitalized patients) and then
provided orally. The median dosage was 1 mg/kg/d (IQR
0.85–1) of prednisone. Adults were nearly twice as likely to
receive SCS compared to children (45% vs. 23%, respectively,
p < 0.0001), and they received them for a much longer duration
(median of 7 days vs. 3 days, respectively, p 0.02). Antibiotics
(mostly β-lactams and macrolides) were widely provided to
children and adults (65% vs. 52%, respectively, p 0.02) although
documented bacterial superinfections were uncommon in both
groups (5.4% vs. 7.6%, respectively, p 0.5). The patients who
had been treated with SCS did not have a higher rate of bac-
terial superinfection (5% vs. 9% if no SCS, p 0.3).
Costs of care
Overall, the costs per case of PEI were signiﬁcantly higher for
adults than children (median V1940, IQR V1310–2637 vs.
V1130, IQR V72–1954, respectively, p < 0.0001). These re-
sults were mainly driven by the higher hospitalization rate and
length for adults (Fig. 2). Indeed, the prices for an external
consultation (V46) or venue to the emergency room (V72)
were standardized regardless of age, and the costs per day of
hospitalization were even higher for children than adults (me-
dian V676, IQR V603–809 vs. V584, IQR V506–739,
respectively, p 0.003).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1041.e1–1041.e7
TABLE 2. CSF ﬁndings of 13 patients who underwent lumbar puncture













1 Brachial plexus neuritis 41 M 7 ND 0.47 3.4 1.3 187
2 Cerebellar syndrome 36 M 5 ND 0.38 3.4 ND < 200
3 Meningeal syndrome 32 F 2 ND 0.37 2.9 1.5 ND
4 Meningeal syndrome 24 F 1 ND 0.24 3.4 ND ND
5 Meningeal syndrome 24 F 6 ND 0.4 3.2 1.9 ND
6 Meningeal syndrome 23 F 1 ND 0.4 3.3 ND ND
7 Meningeal syndrome 22 F 2 ND 0.2 3.4 1.3 ND
8 Meningeal syndrome 20 F 3 ND 0.24 3.2 ND < 200
9 Meningeal syndrome 20 M 1 ND 0.33 4.5 1.4 ND
10 Polyradiculoneuritis 19 F 52 98 0.91 3.1 ND < 200
11 Meningeal syndrome 18 M 76 100 0.25 4.0 ND < 200
12 Meningeal syndrome 9 F 5 ND 0.14 3.1 1.2 ND
13 Cerebellar syndrome 3 F 0 ND 0.22 3.2 ND ND
Mean values 22 12 99 0.35 3.4 1.4
CSF, cerebrospinal ﬂuid; EBV, Epstein-Barr virus; ND, not determined.
CMI Hocqueloux et al. Burden of hospitalizations for EBV 1041.e5Factors associated with clinical severity
In the logistic regression analysis, a high percentage of activated
lymphocytes (20%, i.e. the highest quartile) and vomiting were
predictive of being hospitalized (odds ratio (OR) 4.95, 95%
conﬁdence interval (CI) 1.37–17.96, p 0.01, and OR 3.93, 95%
CI 1.09–14.14, p 0.01, respectively), whereas the absence ofFIG. 2. Hospitalization rate, length and costs according to age (by quartile). R
quartile: 15.5 to 21.4; fourth quartile: 21.5 to 79.1. (A) Hospitalization dispos
(C) Mean hospitalization costs according to age.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infefever decreased the risk of hospitalization (OR 0.23, 95% CI
0.07–0.74, p 0.01) (Table 3).
Patients who were hospitalized stayed a median of 4 days. In
the logistic regression analysis, factors predicting a long dura-
tion of stay (i.e. 4 days or more) at the time of admission were
age (OR 1.58, 95% CI 1.15–2.17, p 0.005, per each increase of aange for ﬁrst quartile: 0.8 to 5.1 years; second quartile: 5.2 to 15.4; third
ition according to age. (B) Mean hospitalization length according to age.
ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1041.e1–1041.e7
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and respiratory discomfort (OR 5.0, 95% CI 1.38–18.14, p
0.01) (Table 3).DiscussionTo our knowledge, our study was the ﬁrst aimed at directly
comparing children and adults presenting with PEI in a hospital
setting. We found some evidence that the later in life EBV is
acquired, the greater its clinical effect, because increasing age
resulted in a higher hospitalization rate and longer duration of
hospital stay.
In our experience, PEI was easily diagnosed in children,
although their symptoms were often nonspeciﬁc. Conversely,
PEI was less easily diagnosed in adults with complex clinical
conditions; this difﬁculty may have led to a higher rate of
hospitalization and diagnostic tools implemented. Typically liver
damage was often overestimated in adults and led to numerous
diagnostic procedures, although no liver failure was recorded.
Such procedures may have lengthened the hospitalization of
adults. However, older age obviously increased the immune-
mediated antiviral responses and subsequently worsened the
clinical condition. The symptoms of PEI are a result of the
inﬁltration of lymphoid organs by speciﬁc activated cells to-
wards EBV, combined with the release of proinﬂammatory
cytokines by these cells [9]. These phenomena are directly
related to the intensity of the EBV virus load and the anti-EBV-
speciﬁc response [13]. We found that the percentage of acti-
vated lymphocytes not only positively correlated with patient
age at PEI onset but also with the length of stay, intensity of
liver abnormalities, enlargement of lymphoid organs (e.g.
generalized lymphadenopathy, hepatomegaly and splenomegaly)
and SCS use (data not shown). These ﬁndings suggest that the
maturity of the immune system in adults certainly accountedTABLE 3. Factors associated with probability of being hospitalized
Characteristic
Risk of hospitalization
Univariate p Multivariate p OR
Age (years) <0.0001 —
Odynophagia 0.14 —
No fever 0.03 0.01 0.23
Vomiting 0.07 0.04 3.93
Flulike syndrome — —
Respiratory discomfort — —
Hepatomegaly — —
Jaundice — —
Percentage of atypical lymphocytes 0.002 0.01 4.95b
CRP (mg/L) 0.0002 —
γ-Glutamyltransferase (ULN) 0.04 —
Aspartate aminotransferase (ULN) 0.08 —
CI, conﬁdence interval; CRP, C-reactive protein; OR, odds ratio; ULN, upper limit of norm
aPer each increase of quartile.
bFor percentage 20%.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectfor worse clinical symptoms. It has recently been reported that
young adults with PEI share a similar transcriptomic signature
with patients with HL, suggesting that EBV can cause uncon-
trolled and deleterious inﬂammatory responses [14]. Although
HL is rarely observed during PEI, it is noteworthy that the only
fatal case in our series was an adult who had developed
complete HL.
During PEI, therapy is administered to treat symptoms
because no antiviral drug has yet been shown to be effective
[3,15]. It is noteworthy that antibiotics were provided to a
majority of patients from both groups included in our study,
even when a PEI diagnosis was identiﬁed. The main indication
for therapy with antibiotics was the observation of any type of
pharyngitis, although this condition is typically observed during
PEI [9]. The use of SCS is also controversial. Although SCS are
usually prescribed for the most symptomatic cases of PEI, a
beneﬁcial role has never been formally demonstrated in ran-
domized trials [16]. In our study, SCS were widely prescribed
to patients with severe odynophagia and intense fatigue; these
symptoms occurred much more frequently in adults than in
children. It is important to note that SCS had no deleterious
effects on the risk of bacterial superinfection.
Except for two patients, all patients included in our study
were healthy individuals without immune suppression. The
adult patients with PEI were almost exclusively white, whereas
a quarter of the children with PEI were born to nonwhite
immigrant families. This result is in agreement with ﬁndings
from the United States in which the socioeconomic environ-
ment strongly inﬂuences age at PEI acquisition [4,7].
In our experience, the incremental costs of PEI care in adults
were mainly related to their more frequent and longer hospi-
talizations. We believe that a faster diagnosis of PEI would allow
patients and doctors to be reassured of the benign nature of the
condition, leading to outpatient monitoring, especially of liver
involvement. Of note, longer hospitalization lengths werefor long-duration stay
Risk of hospitalization ‡4 days
95% CI Univariate p Multivariate p OR 95% CI





0.06 0.01 5.0 1.38–18.14
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CMI Hocqueloux et al. Burden of hospitalizations for EBV 1041.e7reported in other countries a decade ago: 7 days in the United
States [17] and 9 days in Hungary [18].
The strength of our study is that it was a prospective survey
that was conducted over several years in a single centre and
exclusively included well-characterized PEI. Therefore, the
management was homogeneous in time and place, which re-
inforces the validity of the differences we observed between
adults and children. There are also some limitations. Our study
only involved patients presenting to the hospital. Thus, a
recruitment bias cannot be avoided considering that we
recruited the most symptomatic cases requiring urgent and/or
more intensive care, even if reasons that led to hospitalizations
were obviously overestimated (in their severity), at least in
some cases. Presumably the differences we found between
adults and children would be much less marked for patients
exclusively treated in the community.
PEI acquired during adulthood was obviously associated with
a worsened condition that is likely related to the maturation of
antiviral immune responses. Nevertheless, life-threatening
visceral involvement was rare, even in an adult setting. A bet-
ter recognition of the disease in adults, supported by rapid
diagnostic conﬁrmation, is expected to shorten hospital stays
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